AZD6234: a new weekly shot to help adults lose weight

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This global, randomized, double-blind study compares AZD6234 given as a once-weekly subcutaneous shot to placebo in adults with obesity or overweight and at least one weight-related health condition, over 68 weeks. Participants will be assigned to AZD6234 or placebo and monitored for weight change and safety. The trial excludes people with diabetes and certain liver or endocrine conditions to better understand the drug’s effects in the target population. Primary outcomes focus on percent body weight change from baseline at 68 weeks, with ongoing safety assessments. Sites include research centers in Alabama and Arizona.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Males \& females (inclusive of all gender identities) age ≥18 years
* BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence
* Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
* History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime

Exclusion Criteria:

* Obesity primarily caused by other endocrine disorders
* History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening
* Significant hepatobiliary disease and/or any of the following results at Screening:

  * ALT ≥ 3.0 × ULN
  * AST ≥ 3.0 × ULN
  * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome)
* Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

Where it's running

• Research Site
  Dothan, Alabama, United States Recruiting
• Research Site
  Escondido, California, United States Recruiting
• Research Site
  Clearwater, Florida, United States Recruiting
• Research Site
  Stockbridge, Georgia, United States Recruiting
• Research Site
  Champaign, Illinois, United States Recruiting
• Research Site
  Chicago, Illinois, United States Recruiting

+170 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Petrelintide for weight management in adults with overweight or obesity

  This study tests whether petrelintide helps people with overweight or obesity lose weight when combined with a reduced-calorie diet and more exercise, compared with a placebo.

  Recruiting at 8 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 7 other locations · NCT07843498

• Petrelintide for weight management in adults with overweight/obesity and type 2 diabetes

  This study tests whether petrelintide, added to a reduced-calorie diet and more physical activity, helps people with overweight or obesity and type 2 diabetes lose weight more effectively than a placebo.

  Recruiting at 2 sites Phase 3 Hoffmann-La Roche · Los Angeles, California and 1 other locations · NCT07843485

• Petrelintide for weight loss in people with overweight/obesity and heart disease

  This study tests whether petrelintide helps people with overweight or obesity and cardiovascular disease lose weight when added to a reduced-calorie diet and more physical activity, compared with a placebo.

  Recruiting at 3 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 2 other locations · NCT07843472

• AZD6234: a new option for adults with type 2 diabetes and excess weight

  A phase 3 trial tests whether AZD6234 helps adults with type 2 diabetes and overweight or obesity more than placebo over about 68 weeks.

  Recruiting at 58 sites Phase 3 AstraZeneca · Fairhope, Alabama and 229 other locations · NCT07784270

• AZD6234 added to current diabetes therapy to help with weight loss in adults who are overweight or have obesity

  This study tests whether AZD6234, when added to a person’s current incretin-based weight management therapy, can help adults with obesity or overweight lose more weight than a placebo over about 68 weeks.

  Recruiting at 56 sites Phase 3 AstraZeneca · Escondido, California and 95 other locations · NCT07776509

• Switching GLP-1 RA to Maridebart Cafraglutide in Adults with Obesity or Overweight

  This study tests whether switching from a GLP-1 receptor agonist to maridebart cafraglutide is safe and tolerable for adults who are overweight or obese.

  Recruiting at 56 sites Phase 3 Amgen · Pelham, Alabama and 56 other locations · NCT07575399

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.